Aventis Pharmaceuticals Inc.

Jinqi Lu

Kenneth J Bordeau

Michael R Angelastro

Sukanthini Thurairatnam

Jeffrey Stephen Sabol

John Ziqi Jiang

Gregory Shutske

Liang Ma

Joseph T Klein

Stanly John

Keith John Harris

Christopher Loren Vandeusen

Lan Mu

Suzanne C Aldous

Catherine Bomont

Harry Randall Munson

Keith J Harris

This invention is directed to a compound of formula (I): wherein R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine amide compounds as PGDS inhibitors

The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R, R, R, R, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.

3-piperidinylisochroman-5-ols as dopamine agonists

Growing community of inventors

Somerville, NJ, United States of America

Jinqi Lu